Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The key message of the MULTISTARS-AMI trial is that we could show that in patients with STEMI and multivessel disease, immediate multivessel PCI is noninferior to staged multi-vessel PCI based on the 1-year risk for the composite of all cause death, non-fatal myocardial infarction, stroke, unplan...”
Randomized noninferiority trial demonstrates immediate multivessel PCI matches staged PCI for 1-year major adverse events in STEMI, suggesting immediate complete revascularization is safe.
Among patients in hemodynamically stable condition with STEMI and multivessel coronary artery disease, immediate multivessel PCI was noninferior to staged multivessel PCI with respect to the risk of death from any cause, nonfatal myocardial infarction, stroke, unplanned ischemia-driven revascularization, or hospitalization for heart failure at 1 year. (Supported by Boston Scientific; MULTISTARS AMI ClinicalTrials.gov number, NCT03135275.).
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Stähli et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: